SGLT2 Inhibitors
SGLT2 Inhibitors (Class Overview)
Generic name: Dapagliflozin / Empagliflozin / Canagliflozin / Ertugliflozin | Common brands: Farxiga, Jardiance, Invokana, Steglatro
Why choose this class?
- Lowers glucose independent of insulin, with HF and CKD benefits proven even without diabetes.
- Modest weight/BP reduction; low hypoglycemia risk when not combined with insulin/sulfonylurea.
When to avoid or pause
- eGFR below product cutoff, active ketoacidosis, severe dehydration, perioperative/acute illness (pause 3–4 days pre-op per clinician).
Safety & monitoring
- Baseline and periodic kidney labs (eGFR, creatinine).
- Watch for genital mycotic infections, volume depletion, rare euglycemic DKA (check ketones if unwell/low-carb/fasting).
Practical tips
- Hydrate, practice sick-day rules, and educate on ketoacidosis symptoms.
- If on loop/thiazide diuretics, monitor for dizziness/hypotension.
Related single-drug cards
Medical Disclaimer: Education only; not medical advice.
🧪 Key Lab Tests to Monitor
Doctors often track these specific indicators to ensure SGLT2 Inhibitors (Class Overview) is working safely and effectively:
Taking SGLT2 Inhibitors (Class Overview)?
Upload your blood test results. WellAlly will automatically plot your glucose trends alongside your medication timeline.
⚠️ Medical Disclaimer
The information provided here is for educational purposes only and is not intended as medical advice. Always consult with your healthcare provider regarding your medications and lab results. Do not stop taking any medication without talking to your doctor.